Ultrasound and magnetic resonance imaging (MRI) drew attention in 2006 as ways to help diagnose breast cancer and that's exciting news.

Selective COX-2 inhibitors can combine with chemotherapy, endocrine therapy and biotherapy. It is gradually used for adjunctive therapy and provides a new pathway for the therapy of breast cancer.

There is evidence that estrogens through estrogen receptor (er) signaling pathways and estrogen metabolic products participate in the development and progression of breast cancer.